Foley partner David Rosen, co-chair of the firm’s FDA Practice Group is speaking in the Food and Drug Law Institute’s (FDLI) webinar titled “Hatch-Waxman at 40: A Critical Examination of its Past and Future” on September 24.
This webinar will celebrate the 40th anniversary of the Hatch-Waxman Act — an influential piece of legislation that has been crucial in advancing medical innovation and making generic drugs more accessible to patients.
People
Related Insights
May 22, 2026
Foley Viewpoints
New Lawsuit Tests the Limits of Donor-Advised Fund Advisory Privileges
A recent lawsuit seeking to clarify the extent of an advisor’s privileges with respect to a donor-advised fund (DAF) has been filed in…
May 22, 2026
Energy Current
FERC Just Rewrote the Rules for Natural Gas Infrastructure. Here’s What It Means.
Yesterday’s unanimous FERC vote is the most significant natural gas permitting reform in two decades — and its practical implications…
May 22, 2026
Foley Viewpoints
What the Federal Circuit’s Poultry Patent Ruling Says About 'About'
The decision does not appear to prohibit the use of terms such as "about" or "approximately." Rather, it reinforces that such terms may be acceptable where the patent record provides sufficient context for understanding the scope of the claimed range.